Hostname: page-component-7b7567c8c-2n9c9 Total loading time: 0 Render date: 2026-11-16T21:04:58.374Z Has data issue: false hasContentIssue false

Acetylcysteine and lung disease

Review products

MDemedts. et al. High-dose acetylcysteine in idiopathic pulmonaryfibrosis. N Engl J Med. 2005 Nov 24;353(21):2229–42.

M.Decramer et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet. 2005 Apr 30-May 6;365(9470):1552–60.

MPFoschino Barbaro. et al. Oxygen therapy at low flow causes oxidative stress in chronic obstructive pulmonary disease: Prevention by N-acetyl cysteine. Free Radic Res. 2005 Oct;39(10):1111–8.

Published online by Cambridge University Press:  11 September 2013

Get access

In a nutshell

NAC is an antioxidant that stimulates GSH production. As many lung diseases involve oxidative stress, trying antioxidant treatments makes sense.

Clinical evidence supports some role for NAC in treating chronic bronchitis and COPD. Its value in other clinical situations (e.g. idiopathic lung fibrosis) is so far less clear.

Information

Type
Brief Report
Copyright
Copyright © Cambridge University Press 2006

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable